

DAFTAR PUSTAKA

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) With the Special Contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal*. 2021;42(36):3599-726.
2. Arrigo M, Jessup M, Mullens W, Reza N, Shah AM, Sliwa K, et al. Acute Heart Failure. *Nature Reviews Disease Primers*. 2020;6(1):1-15.
3. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano G, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. *Cardiovascular Research*. 2022.
4. Hersunarti N, Siswanto BB, Erwinanto, Nauli SE, Lubis AC, Wiryawan N, et al. *Pedoman Tatalaksana Gagal Jantung*. Edisi Kedua ed. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2020.
5. Reyes EB, Ha J-W, Firdaus I, Ghazi AM, Phrommintikul A, Sim D, et al. Heart Failure Across Asia: Same Healthcare Burden but Differences in Organization of Care. *International Journal of Cardiology*. 2016;223:163-7.
6. Siswanto BB, Radi B, Kalim H, Santoso A, Suryawan R, Antono E, et al. Heart Failure in NCVJ Jakarta and 5 Hospitals in Indonesia. *CVD Prevention and Control*. 2010;5(1):35-8.
7. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the Heart Failure Epidemic: Prevalence, Incidence Rate, Lifetime Risk and Prognosis of Heart Failure: the Rotterdam Study. *European Heart Journal*. 2004;25(18):1614-9.
8. Farmakis D, Filippatos G. Acute Heart Failure: Epidemiology, Classification, and Pathophysiology. In: Tubaro M, Vranckx P, editors. *The ESC Textbook of Intensive and Acute Cardiovascular Care*. Third ed. Oxford: Oxford University Press; 2021. p. 603-14.
9. Choudhary R, Wettersten N, Shah K, Maisel A. Biomarkers in Acute Heart Failure. In: Tubaro M, Vranckx P, editors. *The ESC Textbook of Intensive and Acute Cardiovascular Care*. Third ed. Oxford: Oxford University Press; 2021. p. 409-20.
10. Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, et al. Comparison of BNP and NT-proBNP in Patients with Heart Failure and Reduced Ejection Fraction. *Circulation: Heart Failure*. 2020;13(2):e006541.
11. Cuthbert J, Brown O, Urbinati A, Pan D, Pellicori P, Dobbs K, et al. Hypochloreaemia Following Admission to Hospital with Heart Failure is Common and Associated with an Increased Risk of Readmission or Death: a Report from OPERA-HF. *European Heart Journal Acute Cardiovascular Care*. 2022;11(1):43-52.
12. Grodin JL, Simon J, Hachamovitch R, Wu Y, Jackson G, Halkar M, et al. Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart

- Failure. *Journal of the American College of Cardiology*. 2015;66(6):659-66.
13. Testani JM, Hanberg JS, Arroyo JP, Brisco MA, Ter Maaten JM, Wilson FP, et al. Hypochloraemia is Strongly and Independently Associated with Mortality in Patients with Chronic Heart Failure. *European Journal of Heart Failure*. 2016;18(6):660-8.
 14. Felker GM, Teerlink JR. Diagnosis and Management of Acute Heart Failure. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, editors. *Braunwald's Heart Disease, a Textbook of Cardiovascular Medicine*. Eleventh ed. Philadelphia: Elsevier; 2019. p. 462-89.
 15. Farmakis D, Parissis J, Lekakis J, Filippatos G. Acute heart failure: epidemiology, risk factors, and prevention. *Revista Española de Cardiología*. 2015;68(3):245-8.
 16. Hasenfuss G, Mann DL. Pathophysiology of Heart Failure. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, editors. *Braunwald's Heart Disease, a Textbook of Cardiovascular Medicine*. Eleventh ed. Philadelphia: Elsevier; 2019. p. 442-60.
 17. Rangaswami J, Bhalla V, Blair JE, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: a Scientific Statement from the American Heart Association. *Circulation*. 2019;139(16):e840-e78.
 18. Rivera FB, Alfonso P, Golbin JM, Lo K, Lerma E, Volgman AS, et al. The Role of Serum Chloride in Acute and Chronic Heart Failure: A Narrative Review. *Cardiorenal Medicine*. 2021;11(2):87-98.
 19. Arrigo M, Parissis JT, Akiyama E, Mebazaa A. Understanding Acute Heart Failure: Pathophysiology and Diagnosis. *European Heart Journal Supplements*. 2016;18:G11-G8.
 20. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. 2017;33(11):1342-433.
 21. Felker GM, Teerlink JR. Diagnosis and Management of Acute Heart Failure. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, editors. *Braunwald's Heart Disease, a Textbook of Cardiovascular*. Eleventh ed. Philadelphia: Elsevier; 2019. p. 462-86.
 22. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 2017;70(6):776-803.
 23. Werhahn SM, Becker C, Mende M, Haarmann H, Nolte K, Laufs U, et al. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. *ESC heart failure*. 2022;9(1):100-9.
 24. Nadar SK, Shaikh MM. Biomarkers in Routine Heart Failure Clinical Care. *Cardiac Failure Review*. 2019;5(1):50.
 25. Cao Z, Jia Y, Zhu BJloms. BNP and NT-proBNP as diagnostic biomarkers for cardiac

dysfunction in both clinical and forensic medicine. 2019;20(8):1820.



26. Emdin M, Aimo A, Castiglione V, Vergaro G, Georgiopoulos G, Saccaro LF, et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week. *Journal of the American College of Cardiology*. 2020;76(15):1795-807.
27. Cao Z, Jia Y, Zhu B. BNP and NT-proBNP as Diagnostic Biomarkers for Cardiac Dysfunction in Both Clinical and Forensic Medicine. *International Journal of Molecular Sciences*. 2019;20(8):1820.
28. Ezekowitz JA, O'Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. *Canadian Journal of Cardiology*. 2017;33(11):1342-433.
29. Eggers KM, Venge P, Lind L. Prognostic Usefulness of the Change in N-terminal pro B-type natriuretic Peptide Levels to Predict Mortality in a Single Community Cohort Aged \geq 70 Years. *The American Journal of Cardiology*. 2013;111(1):131-6.
30. Poortvliet R, de Craen A, Gussekloo J, de Ruijter W. Increase in N-terminal pro-Brain Natriuretic Peptide Levels, Renal Function and Cardiac Disease in the Oldest Old. *Age and Ageing*. 2015;44(5):841-7.
31. Tsutamoto T, Sakai H, Yamamoto T, Nakagawa Y. Renal clearance of N-Terminal pro-brain natriuretic peptide is markedly decreased in chronic kidney disease. *Circulation Reports*. 2019:CR-19-0063.
32. Wieshammer S, Dreyhaupt J, Basler B. Elevated levels of N-terminal pro-brain natriuretic peptide in patients with chronic dyspnea and moderate renal dysfunction: decreased clearance or increased cardiac stress. *Cardiorenal Medicine*. 2011;1(3):156-63.
33. Buettner P, Schumacher K, Dinov B, Zeynalova S, Sommer P, Bollmann A, et al. Role of NT-proANP and NT-proBNP in Patients with Atrial Fibrillation: Association with Atrial Fibrillation Progression Phenotypes. *Heart Rhythm*. 2018;15(8):1132-7.
34. Staszewsky L, Meessen J, Novelli D, Wienhues-Thelen U, Disertori M, Maggioni AP, et al. Total NT-proBNP, a Novel Biomarker in Atrial Fibrillation. A Mechanistic Analysis of the GISSI-AF Trial. *MedRxiv*. 2020.
35. Chouairi F, Pacor J, Miller PE, Fuery MA, Caraballo C, Sen S, et al. Effects of Atrial Fibrillation on Heart Failure Outcomes and NT-proBNP Levels in the GUIDE-IT Trial. *Mayo Clinic Proceedings: Innovations, Quality & Outcomes*. 2021;5(2):447-55.
36. Santema BT, Chan MM, Tromp J, Dokter M, van der Wal HH, Emmens JE, et al. The Influence of Atrial Fibrillation on the Levels of NT-proBNP Versus GDF-15 in Patients with Heart Failure. *Clinical Research in Cardiology*. 2020;109(3):331-8.
37. Ocak T, Erdem A, Duran A, Tekelioğlu ÜY, Öztürk S, Ayhan SS, et al. The diagnostic significance of NT-proBNP and troponin I in emergency department patients presenting with palpitations. 2013;68:543-7.
38. García-Carmona J, Conesa-García E, Vidal-Mena D, González-Morales M, Ramos-

Arenas V, Sánchez-Vizcaíno-Buendía C, et al. Increased plasma levels



- of N-terminal pro-B-type natriuretic peptide as biomarker for the diagnosis of cardioembolic ischaemic stroke. 2022.
39. Giannakoulas G, Hatzitolios A, Karvounis H, Koliakos G, Charitandi A, Dimitroulas T, et al. N-terminal pro-brain natriuretic peptide levels are elevated in patients with acute ischemic stroke. 2005;56(6):723-30.
 40. Fonseca A, Matias J, e Melo T, Pires C, Geraldes R, Canhão P, et al. Time course of NT-pro BNP levels after acute ischemic stroke. 2013;128(4):235-40.
 41. Okoronkwo EJF. The influence of admission serum N-terminal pro-brain natriuretic peptide levels on the 30-day outcome following acute stroke. Faculty of Internal Medicine. 2017.
 42. Di Castelnuovo A, Veronesi G, Costanzo S, Zeller T, Schnabel RB, de Curtis A, et al. NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and the Risk of Stroke: Results from the BiomarCaRE Consortium. 2019;50(3):610-7.
 43. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch T, Weiß C, et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. 2005;112(4):527-34.
 44. Khalid U, Wruck LM, Quibrera PM, Bozkurt B, Nambi V, Virani SS, et al. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: the Atherosclerosis Risk in Communities Surveillance Study. 2017;233:61-6.
 45. Marie R, Philippe MJCM. B-type natriuretic peptide and obesity in heart failure: a mysterious but important association in clinical practice. 2020(1).
 46. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology. 2017;70(6):776-803.
 47. Santaguida PL, Don-Wauchope AC, Ali U, Oremus M, Brown JA, Bustamam A, et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. 2014;19(4):507-19.
 48. Golcuk Y, Golcuk B, Velibey Y, Oray D, Atilla OD, Colak A, et al. Predictive cutoff point of admission N-terminal pro-B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure. 2013;31(8):1191-5.
 49. Kataoka H. Chloride in Heart Failure Syndrome: Its Pathophysiologic Role and Therapeutic Implication. Cardiology and Therapy. 2021;10(2):407-28.
 50. Berend K, van Hulsteijn LH, Gans ROJEjoim. Chloride: the queen of electrolytes? 2012;23(3):203-11.
 51. Ter Maaten JM, Damman K, Hanberg JS, Givertz MM, Metra M, O'Connor CM, et al. Hypochloremia, Diuretic Resistance, and Outcome in Patients with Acute Heart Failure. Circulation: Heart Failure. 2016;9(8):e003109.
 52. Kondo T, Yamada T, Tamaki S, Morita T, Furukawa Y, Iwasaki Y, et al. Serial Change in Serum Chloride During Hospitalization Could Predict Heart Failure Death in Acute Decompensated Heart Failure Patients. Circulation Journal.

2018;82(4):1041-50.



53. Cappola TP, Matkovich SJ, Wang W, Van Booven D, Li M, Wang X, et al. Loss-of-function DNA Sequence Variant in the CLCNKA Chloride Channel Implicates the Cardio-renal Axis in Interindividual Heart Failure Risk Variation. *Proceedings of the National Academy of Sciences*. 2011;108(6):2456-61.
54. Grodin JL, Mullens W, Dupont M, Taylor DO, McKie PM, Starling RC, et al. Hemodynamic Factors Associated with Serum Chloride in Ambulatory Patients with Advanced Heart Failure. *International Journal of Cardiology*. 2018;252:112-6.
55. Hanberg JS, Rao V, Ter Maaten JM, Laur O, Brisco MA, Perry Wilson F, et al. Hypochloremia and Diuretic Resistance in Heart Failure: Mechanistic Insights. *Circulation: Heart Failure*. 2016;9(8):e003180.
56. De Bacquer D, De Backer G, De Buyzere M, Kornitzer M. Is Low Serum Chloride Level a Risk Factor for Cardiovascular Mortality? *Journal of Cardiovascular Risk*. 1998;5(3):177-84.
57. Cuthbert JJ, Pellicori P, Rigby A, Pan D, Kazmi S, Shah P, et al. Low Serum Chloride in Patients with Chronic Heart Failure: Clinical Associations and Prognostic Significance. *European Journal of Heart Failure*. 2018;20(10):1426-35.
58. Grodin JL, Sun J-L, Anstrom KJ, Chen HH, Starling RC, Testani JM, et al. Implications of serum chloride homeostasis in acute heart failure (from ROSE-AHF). 2017;119(1):78-83.
59. Grodin JL, Verbrugge FH, Ellis SG, Mullens W, Testani JM, Tang WW. Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. *Circulation: Heart Failure*. 2016;9(1):e002453.
60. Seo M, Watanabe T, Yamada T, Yano M, Hayashi T, Nakagawa A, et al. Prognostic Significance of Serum Chloride Level in Heart Failure Patients with Preserved Ejection Fraction. *ESC Heart Failure*. 2022;9(2):1444-53.
61. Zhang Y, Peng R, Li X, Yu J, Chen X, Zhou Z. Serum Chloride as a Novel Marker for Adding Prognostic Information of Mortality in Chronic Heart Failure. *Clinica Chimica Acta*. 2018;483:112-8.
62. Fu Z, An L, Lu X, Sheng L, Liu H. Serum Chloride Is Inversely Associated With 3 Months Outcomes in Chinese Patients With Heart Failure, a Retrospective Cohort Study. *Frontiers in Cardiovascular Medicine*. 2022;9.
63. Ferreira JP, Girerd N, Duarte K, Coiro S, McMurray JJ, Dargie HJ, et al. Serum Chloride and Sodium Interplay in Patients with Acute Myocardial Infarction and Heart Failure with Reduced Ejection Fraction: an Analysis from the High-risk Myocardial Infarction Database Initiative. *Circulation: Heart Failure*. 2017;10(2):e003500.
64. Marchenko R, Sigal A, Wasser TE, Reyer J, Green J, Mercogliano C, et al. Hypochloremia and 30 Day Readmission Rate in Patients with Acute Decompensated Heart Failure. *ESC Heart Failure*. 2020;7(3):903-7.
65. Nakamura J, Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, et al. Hypochloremia Predicts Poor Clinical Outcome in Patients With Acute Decompensated Heart Failure Irrespective of Left Ventricular Ejection

- Fraction. *Circulation*. 2017;136:A17547-A.
66. Shirotani S, Jujo K, Kishihara M, Watanabe S, Endo N, Takada T, et al. Renin- Angiotensin System Inhibitor Exerts Prognostic Effect in HFpEF Patients With Low Chloride Level. *Circulation*. 2021;144:A13457-A.
67. Kondo T, Yamada T, Morita T, Furukawa Y, Tamaki S, Iwasaki Y, et al. Prognostic Value of Serial Change of Serum Chloride Level During Hospitalization in Patients With Acute Decompensated Heart Failure. *Circulation*. 2016;134:A17491-A.
68. Cuthbert JJ, Bhandari S, Clark AL. Hypochloraemia in Patients With Heart Failure: Causes and Consequences. *Cardiology and Therapy*. 2020;9(2):333-47.
69. Dahlan MS. Besar Sampel dalam Penelitian Kedokteran dan Kesehatan Jakarta: *Epidemiologi Indonesia*; 2019. 49-52 p.
70. Takagi K, Kimmoun A, Sato N, Mebazaa A. Management of acute heart failure during an early phase. *International Journal of Heart Failure*. 2020;2(2):91-110.
71. Krittayaphong R, Nomsawadi V, Muenkaew M, Miniphan M, Yindeengam A, Udompunturak S. Accuracy of ECG criteria for the diagnosis of left ventricular hypertrophy: a comparison with magnetic resonance imaging. *Journal of the Medical Association of Thailand*. 2013;96:S124-32.
72. Urso C, Brucculeri S, Caimi G. Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications. *Heart failure reviews*. 2015;20(4):493-503.
73. King M, Kingery JE, Casey B. Diagnosis and evaluation of heart failure. *American family physician*. 2012;85(12):1161-8.

